Literature DB >> 19328416

Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities.

Laszlo Hegedüs1.   

Abstract

Currently there are three well-established treatment options for hyperthyroid Graves' disease (GD): antithyroid drug therapy with thionamides (ATD), radioactive iodine treatment with (131)I, and thyroid surgery. This article reviews the current evidence so the reader can evaluate advantages and disadvantages of these treatment modalities. Surgery is rarely used, except for patients who have a large goiter or ophthalmopathy. Fewer than 50% of patients treated with ATD remain in long-term remission. Therefore, radioactive iodine is used increasingly. No data as yet support the routine use of biologic therapies (eg, rituximab). Prospective, randomized studies comparing available and any novel therapeutic options for GD are needed. The focus of these studies should include, but not be limited to, cost and quality of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328416     DOI: 10.1016/j.ecl.2009.01.009

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  13 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  37-year-old woman with palpitations and fatigue.

Authors:  Amit Noheria; Sahil Khanna; Colin P West
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

3.  Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial.

Authors:  Murat Faik Erdoğan; Özgür Demir; Reyhan Ünlü Ersoy; Kamile Gül; Berna İmge Aydoğan; Ziynet Alphan Üç; Türkan Mete; Sibel Ertek; Uğur Ünlütürk; Bekir Çakır; Yalçın Aral; Serdar Güler; Sevim Güllü; Demet Çorapçıoğlu; Selçuk Dağdelen; Gürbüz Erdoğan
Journal:  Eur Thyroid J       Date:  2016-04-26

4.  Identifying predictors of a difficult thyroidectomy.

Authors:  Valerie M Mok; Sarah C Oltmann; Herbert Chen; Rebecca S Sippel; David F Schneider
Journal:  J Surg Res       Date:  2014-03-19       Impact factor: 2.192

5.  The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors:  K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  Systemic adverse events following rituximab therapy in patients with Graves' disease.

Authors:  D El Fassi; C H Nielsen; P Junker; H C Hasselbalch; L Hegedüs
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

7.  Thyroidectomy as primary treatment optimizes body mass index in patients with hyperthyroidism.

Authors:  David F Schneider; Ratnam Nookala; Taylor J Jaraczewski; Herbert Chen; Carmen C Solorzano; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-02-13       Impact factor: 5.344

8.  Failure of radioactive iodine in the treatment of hyperthyroidism.

Authors:  David F Schneider; Philip E Sonderman; Michaela F Jones; Kristin A Ojomo; Herbert Chen; Juan C Jaume; Diane F Elson; Scott B Perlman; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-07-08       Impact factor: 5.344

9.  Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.

Authors:  L Bartalena; P E Macchia; C Marcocci; M Salvi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

10.  Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.

Authors:  Torquil Watt; Per Cramon; Jakob Bue Bjorner; Steen Joop Bonnema; Ulla Feldt-Rasmussen; Christian Gluud; Jeppe Gram; Jane Lindschou Hansen; Laszlo Hegedüs; Nils Knudsen; Pernille Bach-Mortensen; Runa Nolsøe; Birte Nygaard; Flemming Pociot; Maria Skoog; Per Winkel; Ase Krogh Rasmussen
Journal:  Trials       Date:  2013-04-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.